Persons
Webseiten-Inhalte
Researcher of the MedUni Vienna
...Marko Grahovac, MSc Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: PHD Student ORCID: 0000-0002-3323-778XT +43 1 40400-55850 marko.grahovac@meduniwien.ac.at Keywords Artificial Intelligence; Data Mining; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac Lukas Kenner Kilian Kluge Research interests Machine learning, image processing, personalized medicine, tumour characterization Techniques...
https://www.meduniwien.ac.at/web/en/research/researcher-profiles/researcher-profiles/index.php?id=688&res=marko_grahovac
Detailsite | MedUni Vienna
...All News Vienna (12th September 2011) – The MedUni Vienna and AKRON Molecules have signed a licence and cooperation agreement for the development of a new therapy with few side effects for a group of rare, malignant tumours in the lymphatic system. Lukas Kenner from the Clinical...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/?cHash=af4aca4673bd6a53282ca87e2a84a8df&tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=725
Detailsite | MedUni Vienna
...All News Vienna (12th September 2011) – The MedUni Vienna and AKRON Molecules have signed a licence and cooperation agreement for the development of a new therapy with few side effects for a group of rare, malignant tumours in the lymphatic system. Lukas Kenner from the Clinical...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/?tx_news_pi1%5Bnews%5D=725&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=af4aca4673bd6a53282ca87e2a84a8df
Detailsite | MedUni Vienna
...All News Vienna (12th September 2011) – The MedUni Vienna and AKRON Molecules have signed a licence and cooperation agreement for the development of a new therapy with few side effects for a group of rare, malignant tumours in the lymphatic system. Lukas Kenner from the Clinical...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/meduni-vienna-and-akron-molecules-cooperate-in-the-fight-against-aggressive-tumours-in-the-lymphatic-system/?L=3
Detailsite | MedUni Vienna
...All News Vienna (12th September 2011) – The MedUni Vienna and AKRON Molecules have signed a licence and cooperation agreement for the development of a new therapy with few side effects for a group of rare, malignant tumours in the lymphatic system. Lukas Kenner from the Clinical...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/meduni-wien-und-akron-molecules-kooperieren-im-kampf-gegen-aggressive-tumore-im-lymphatischen-system/?L=3
Detailsite | MedUni Vienna
... 'gefitinib' therefore kills tumour cells in more than 80 percent of patients," Lukas Kenner from the LBI-CR, who also works as a professor at MedUni Vienna, explained to the Austrian Press Agency APA.The therapy often quickly loses steam despite a good initial effect. The team of researchers has now...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/?tx_news_pi1%5Bnews%5D=347&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=902e71bd26d98af349dfbc2068949516
Detailsite | MedUni Vienna
... 'gefitinib' therefore kills tumour cells in more than 80 percent of patients," Lukas Kenner from the LBI-CR, who also works as a professor at MedUni Vienna, explained to the Austrian Press Agency APA.The therapy often quickly loses steam despite a good initial effect. The team of researchers has now...
https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/lung-cancer-approach-for-new-combined-treatment/?L=3
News
... dieser Situation könnte z.B. eine Chemotherapie wesentlich besser wirken„Ziel ist es nun, Substanzen zu finden, die diese Autophagie blockieren können. Danach könnten die klinische Studien starten“, sagt Lukas Kenner vom Klinischen Institut für Pathologie der MedUni Wien und vom Ludwig-Boltzmann-Institut...
https://www.meduniwien.ac.at/web/index.php?id=131&L=3&tx_news_pi1%5Bnews%5D=2176&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=4d0964903eda75797f1178d8c796410c
News
... dieser Situation könnte z.B. eine Chemotherapie wesentlich besser wirken„Ziel ist es nun, Substanzen zu finden, die diese Autophagie blockieren können. Danach könnten die klinische Studien starten“, sagt Lukas Kenner vom Klinischen Institut für Pathologie der MedUni Wien und vom Ludwig-Boltzmann-Institut...
https://www.meduniwien.ac.at/web/ueber-uns/news/detail/lungenkrebs-selbstschutz-von-tumorzellen-kann-blockiert-werden/?L=3
News
... dieser Situation könnte z.B. eine Chemotherapie wesentlich besser wirken„Ziel ist es nun, Substanzen zu finden, die diese Autophagie blockieren können. Danach könnten die klinische Studien starten“, sagt Lukas Kenner vom Klinischen Institut für Pathologie der MedUni Wien und vom Ludwig-Boltzmann-Institut...
https://www.meduniwien.ac.at/web/ueber-uns/news/detail/?tx_news_pi1%5Bnews%5D=2176&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=4d0964903eda75797f1178d8c796410c